Scarica l'app Stockscreener
15.11
5.86%
-0.94
Precedente Chiudi:
$16.05
Aprire:
$16.06
Volume 24 ore:
771.62K
Relative Volume:
0.97
Capitalizzazione di mercato:
$1.59B
Reddito:
-
Utile/perdita netta:
$-150.70M
Rapporto P/E:
-9.7484
EPS:
-1.55
Flusso di cassa netto:
$-125.67M
1 W Prestazione:
-3.45%
1M Prestazione:
+3.00%
6M Prestazione:
+30.60%
1 anno Prestazione:
-49.62%
Intervallo 1D:
$14.67
$16.06
Intervallo di 1 settimana:
$14.67
$16.51
Portata 52W:
$10.60
$38.12
Edgewise Therapeutics Inc Stock (EWTX) Company Profile
Nome
Edgewise Therapeutics Inc
Settore
Industria
Telefono
720-262-7002
Indirizzo
1715 38TH ST, BOULDER
Confronta EWTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
15.11 | 1.69B | 0 | -150.70M | -125.67M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-25 | Iniziato | Goldman | Neutral |
| 2025-07-30 | Iniziato | Raymond James | Strong Buy |
| 2025-06-30 | Iniziato | H.C. Wainwright | Buy |
| 2025-04-30 | Iniziato | Guggenheim | Buy |
| 2025-04-02 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2025-01-22 | Iniziato | Stifel | Hold |
| 2024-11-22 | Iniziato | Evercore ISI | Outperform |
| 2024-03-07 | Iniziato | Piper Sandler | Overweight |
| 2023-05-01 | Iniziato | Truist | Buy |
| 2022-08-25 | Downgrade | Goldman | Neutral → Sell |
| 2022-04-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-01-28 | Iniziato | Goldman | Neutral |
Mostra tutto
Edgewise Therapeutics Inc Borsa (EWTX) Ultime notizie
Can Edgewise Therapeutics Inc. stock beat analyst upgrades2025 Institutional Moves & Weekly Chart Analysis and Guides - newser.com
Why Edgewise Therapeutics Inc. is moving todayShare Buyback & Safe Swing Trade Setups - newser.com
What analysts say about Edgewise Therapeutics Inc stockMACD Trading Signals & Fast Growing Stocks - earlytimes.in
What drives Edgewise Therapeutics Inc stock priceHigh Frequency Trading Trends & High Return Stock Ideas - earlytimes.in
How high can Edgewise Therapeutics Inc. stock goJuly 2025 Summary & Free Technical Confirmation Trade Alerts - newser.com
Edgewise Therapeutics (NASDAQ:EWTX) Stock Price Down 5.1%Here's What Happened - MarketBeat
Can a trend reversal in Edgewise Therapeutics Inc. lead to recoveryGDP Growth & Safe Entry Trade Reports - newser.com
Applying Elliott Wave Theory to Edgewise Therapeutics Inc.Portfolio Return Report & Technical Entry and Exit Tips - newser.com
Building trade automation scripts for Edgewise Therapeutics Inc.Trade Entry Report & Reliable Price Breakout Signals - newser.com
Weiss Ratings Reaffirms "Sell (D-)" Rating for Edgewise Therapeutics (NASDAQ:EWTX) - MarketBeat
Key metrics from Edgewise Therapeutics Inc.’s quarterly dataJuly 2025 Fed Impact & High Accuracy Investment Signals - newser.com
How Investors May Respond To Edgewise Therapeutics (EWTX) Long-Term Sevasemten Data at World Muscle Congress - Yahoo Finance
Edgewise Therapeutics (EWTX): Evaluating Valuation as New Long-Term Clinical Data Sparks Investor Interest - Yahoo Finance
How Investors Are Reacting To Edgewise Therapeutics (EWTX) Unveiling Long-Term Data for Sevasemten at WMS 2025 - Sahm
Edgewise Therapeutics presents muscular dystrophy research at Vienna conference - Traders Union
Tools to monitor Edgewise Therapeutics Inc. recovery probabilityWeekly Trend Report & Long-Term Growth Stock Strategies - newser.com
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules - Eastern Progress
Edgewise Therapeutics (EWTX): Reviewing Valuation After Recent Momentum Shifts - Sahm
Edgewise Therapeutics, Inc. $EWTX Shares Acquired by HighMark Wealth Management LLC - MarketBeat
Best data tools to analyze Edgewise Therapeutics Inc. stockTrade Entry Report & Smart Money Movement Tracker - newser.com
Will earnings trigger a reversal in Edgewise Therapeutics Inc.Weekly Trend Recap & Short-Term Swing Trade Alerts - newser.com
Edgewise Therapeutics reports inducement grants as permitted by Nasdaq listing rules - MarketScreener
Breakthrough Muscular Dystrophy Treatment: Edgewise's Sevasemten Shows Disease Stabilization in Key Trials - Stock Titan
247K Stock Options: Edgewise Grants Inducement Awards (15K RSUs) to 9 New Hires - Stock Titan
Wall Street Analysts Think Edgewise Therapeutics (EWTX) Could Surge 182%: Read This Before Placing a Bet - MSN
Is Edgewise Therapeutics Inc a good long term investmentShort-Term Trading Alerts & Set Up Real-Time Alerts – It’s Free - earlytimes.in
Edgewise Therapeutics (NASDAQ:EWTX) Raised to "Hold" at The Goldman Sachs Group - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Trading Down 8.5%Here's Why - MarketBeat
The Goldman Sachs Group Begins Coverage on Edgewise Therapeutics (NASDAQ:EWTX) - MarketBeat
Goldman Sachs Initiates Coverage of Edgewise Therapeutics (EWTX) with Neutral Recommendation - Nasdaq
Goldman Sachs initiates Edgewise Therapeutics stock with Neutral rating By Investing.com - Investing.com Canada
Edgewise Therapeutics (NASDAQ:EWTX) Trading 8.5% HigherShould You Buy? - MarketBeat
Pattern recognition hints at Edgewise Therapeutics Inc. upsideWeekly Volume Report & Capital Protection Trading Alerts - newser.com
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives $40.55 Average Price Target from Analysts - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Trading Down 4.8%Should You Sell? - MarketBeat
Full technical analysis of Edgewise Therapeutics Inc. stockAnalyst Upgrade & Risk Adjusted Buy/Sell Alerts - newser.com
Will Edgewise Therapeutics Inc. continue its uptrendPortfolio Return Summary & High Conviction Investment Ideas - newser.com
Guidance Update: Can Edgewise Therapeutics Inc expand its profit marginsLayoff News & Daily Profit Focused Screening - خودرو بانک
Trade Recap: Is Edgewise Therapeutics Inc subject to activist investor interest2025 Earnings Impact & Accurate Technical Buy Alerts - خودرو بانک
Will Edgewise Therapeutics Inc. benefit from macro trendsQuarterly Risk Review & Safe Capital Growth Stock Tips - newser.com
Institutional scanner results for Edgewise Therapeutics Inc.2025 Retail Activity & Fast Exit Strategy with Risk Control - newser.com
What does recent volatility data suggest for Edgewise Therapeutics Inc.Market Weekly Review & AI Driven Price Predictions - newser.com
Analyzing recovery setups for Edgewise Therapeutics Inc. investorsJuly 2025 Trade Ideas & Real-Time Market Sentiment Alerts - newser.com
What indicators show strength in Edgewise Therapeutics Inc.July 2025 WrapUp & Weekly Setup with ROI Potential - newser.com
Predicting Edgewise Therapeutics Inc. trend using moving averages2025 Performance Recap & Weekly High Momentum Picks - newser.com
Aug Mood: Is Edgewise Therapeutics Inc. a cyclical or defensive stockJuly 2025 Macro Moves & Low Risk Growth Stock Ideas - خودرو بانک
Evaluating Edgewise Therapeutics Inc. with trendline analysisEarnings Overview Report & Precise Buy Zone Tips - newser.com
Goldman Sachs Group Inc. Has $8.07 Million Holdings in Edgewise Therapeutics, Inc. $EWTX - MarketBeat
Should you wait for a breakout in Edgewise Therapeutics Inc.July 2025 Recap & Reliable Entry Point Trade Alerts - newser.com
Edgewise Therapeutics Inc Azioni (EWTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Edgewise Therapeutics Inc Azioni (EWTX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Russell Alan J | Chief Scientific Officer |
Aug 26 '25 |
Sale |
14.60 |
100,000 |
1,459,760 |
23,400 |
5.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):